Novavax Inc. has the green light to start a late-stage clinical trial for its seasonal flu vaccine, less than six months after a phase 3 trial for its respiratory syncytial virus vaccine failed and sent the company’s future into question. The Gaithersburg biotech, having finalized its phase 3 study design for NanoFlu with the Food and Drug Administration, expects to initiate the trial this fall and report results in the first quarter of next year, CEO Stanley Erck discussed on an earnings call…
from https://www.bizjournals.com/baltimore/news/2019/08/08/novavax-looks-to-next-flu-vaccine-trial-following.html?ana=RSS&s=article_search
via https://baltimorecheckbook.tumblr.com/post/186862803472
No comments:
Post a Comment